胃保护性天然聚合物有助于三重药物治疗,以消灭Helicobacter pylori
Rajeshpavan Ampapuram1, Gopinath Subramaniyan2, Ramakrishnan Subburaya Rajendran3
1Research scholar, Department of Pharmaceutics, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Porur, Chennai, Tamil Nadu, India.
Pakistan journal of pharmaceutical sciences
|September 28, 2024
概括
这项研究开发了一种新型的三重疗法,使用含有天然粘液的美特罗尼达和克拉里思罗米辛微球,加上潘托普拉迷你片,以有效地根除Helicobacter pylori.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 微生物学 微生物学
背景情况:
- 杆菌感染是胃潰瘍和胃疾病的主要原因之一.
- 现有的疗法面临着有效性和副作用的挑战.
- 需要新的药物输送系统来改善H. pylori的根除.
研究的目的:
- 探索使用浮动微球和肠道涂层迷你片来根除H. pylori的三重疗法.
- 调查 Plantago ovata 种子粘液 (POSM) 和 Abelmoschus esculentus 水果粘液 (AEFM) 在药物输送中的潜力.
- 使用中央复合材料设计优化配方参数.
主要方法:
- 使用POSM和AEFM分别制备甲化 (MNZ) 和清红素 (CMN) 浮动微球.
- 在硬凝囊中封装肠膜涂层的潘托普拉酸盐 (PZS) 迷你片.
- 使用中央复合设计和设计专家软件优化微球和迷你平板电脑的性能.
主要成果:
- 微球显示出良好的药物捕获效果和延长漂浮时间.
- 肠膜涂层迷你片显示了适当的涂层厚度.
- 配方成功测试,表明对H. pylori根除潜力的积极反应.
结论:
- 开发的三重疗法,将MNZ和CMN微球与PZS迷你片结合起来,显示出有效根除H. pylori的巨大潜力.
- POSM和AEFM作为有效的粘膜聚合物,增强胃保护和治疗的特性.
- 这种新的配方提供了一种有希望的方法来对抗H. pylori感染.
更多相关视频
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
328
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
328
01:26Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
360
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
360
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
372
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
372
01:23Gastritis III: Clinical Manifestations and Management
172
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
172
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356